Kynam Capital Management’s UroGen Pharma URGN Stock Holding History

Kynam Capital Management’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$89.6M	Buy	2,434,207 +186,814	+8%	+$5.06M	4.95%	9
2026 Q1	$40.4M	Buy	+2,247,393	New	+$45.1M	2.49%	12
2025 Q4	–	Sell	-282,412	Closed	-$6.94M	–	40
2025 Q3	$6.94M	Sell	282,412 -374,161	-57%	-$6.72M	0.52%	30
2025 Q2	$9M	Buy	656,573 +631,573	+2,526%	+$6.06M	0.97%	20
2025 Q1	$277K	Buy	+25,000	New	+$267K	0.02%	32

Other funds holding URGN

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Kynam Capital Management's URGN Position: Q2 2026 in Review

Kynam Capital Management increased its UroGen Pharma (URGN) stake by 8.3% in Q2 2026, buying an estimated $5.06M and bringing the position to 2,434,207 shares worth $89.6M. The position accounts for 4.95% of the portfolio, ranked #9.

Kynam Capital Management first reported a position in URGN in Q1 2025 and has held it in 5 quarters since. 189 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

Kynam Capital Management held 2,434,207 shares of UroGen Pharma worth $89.6M as of Q2 2026.
Kynam Capital Management bought 186,814 UroGen Pharma shares in Q2 2026, an estimated $5.06M.
UroGen Pharma made up 4.95% of Kynam Capital Management's portfolio in Q2 2026, its #9 holding.
Kynam Capital Management first reported a position in UroGen Pharma in Q1 2025 and has held it in 5 quarters since.
189 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on Kynam Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.